MoleculeDX brings molecular testing and machine learning together to support earlier detection of hepatocellular carcinoma, the most common form of primary liver cancer. Its Fusion-detect blood test analyzes cancer-associated fusion transcripts in serum and uses a computational model to identify patterns associated with the disease. At-home blood collection through contracted partners helps make testing more accessible. [1]
A University of Pittsburgh spinout, MoleculeDX builds on research into the molecular signals released by liver cancers. The company operates a CLIA-certified, COLA-accredited clinical laboratory and provides a digital platform for ordering tests, coordinating collection and receiving results, connecting laboratory innovation with practical screening support. [2] [3]